Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis
- PMID: 28656100
- PMCID: PMC5474905
- DOI: 10.4103/ijpvm.IJPVM_413_16
Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis
Abstract
Human papillomavirus (HPV) can induce cervical intraepithelial neoplasia (CIN). Vaccination against HPV can play an important role in CIN prevention. This study aims to estimate the efficacy of L1 protein vaccines (Cervarix and Gardasil) in CIN 1, 2, 3 risk reduction using meta-analysis. Relevant articles were identified by two independent researchers searching international databanks. After application of inclusion/exclusion criteria and quality assessment, eligible articles were entered into the final meta-analysis. Inverse variance method and fixed effect model were used to combine the results of the primary studies. The heterogeneity between the results was assessed using Cochrane and I2 indices. Of 11,530 evidence identified during the primary search, three papers were found eligible for meta-analysis, including 7213 participants in the intervention groups and 7170 healthy controls. The efficacy (95% confidence interval) of HPV 6, 11, 16, 18 monovalent and quadrivalent vaccines against CIN 1, CIN 2, and CIN 3 were estimated as of 95% (88-98), 97% (85-99), and 95% (78-99), respectively. This study showed that L1 protein vaccines Cervarix and Gardasil are highly protective vaccines playing an effective role in the prevention of HPV 6, 11, 16, 18 which are responsible for CIN 1, CIN 2, and CIN 3.
Keywords: Cervical intraepithelial neoplasia; efficacy; human papillomavirus; meta-analysis; vaccine.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Current prophylactic HPV vaccines and gynecologic premalignancies.Curr Opin Obstet Gynecol. 2009 Dec;21(6):457-64. doi: 10.1097/GCO.0b013e328332c910. Curr Opin Obstet Gynecol. 2009. PMID: 19923989 Review.
-
Human papillomavirus vaccines.Ann Pharmacother. 2006 Jul-Aug;40(7-8):1344-52. doi: 10.1345/aph.1G723. Epub 2006 Jul 18. Ann Pharmacother. 2006. PMID: 16849621 Review.
-
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18. Adv Ther. 2009. PMID: 20024678 Review.
-
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.Hum Vaccin. 2009 Oct;5(10):705-19. doi: 10.4161/hv.5.10.9518. Epub 2009 Oct 14. Hum Vaccin. 2009. PMID: 19684472 Clinical Trial.
-
Evaluation of the Therapeutic Effect of Quadrivalent Human Papillomavirus (HPV) Vaccination on Cervical Intraepithelial Neoplasia Lesions.Indian J Surg Oncol. 2023 Jun;14(2):504-509. doi: 10.1007/s13193-022-01657-w. Epub 2022 Oct 1. Indian J Surg Oncol. 2023. PMID: 37324297 Free PMC article.
Cited by
-
The prevalence and genotyping of human papillomavirus in patients with oral tumors in health centers and clinics of Mazandaran in Iran.Virusdisease. 2018 Sep;29(3):297-302. doi: 10.1007/s13337-018-0472-2. Epub 2018 Jul 31. Virusdisease. 2018. PMID: 30159363 Free PMC article.
-
Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.Front Immunol. 2020 Jun 9;11:1100. doi: 10.3389/fimmu.2020.01100. eCollection 2020. Front Immunol. 2020. PMID: 32582186 Free PMC article. Review.
-
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018. Viruses. 2019. PMID: 31877975 Free PMC article. Review.
-
Current status and future directions for the development of human papillomavirus vaccines.Front Immunol. 2024 Jun 25;15:1362770. doi: 10.3389/fimmu.2024.1362770. eCollection 2024. Front Immunol. 2024. PMID: 38983849 Free PMC article. Review.
-
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9. Vaccine. 2018. PMID: 30314913 Free PMC article. Clinical Trial.
References
-
- Cho HJ, Oh YK, Kim YB. Advances in human papilloma virus vaccines: A patent review. Expert Opin Ther Pat. 2011;21:295–309. - PubMed
-
- Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine. 2004;22:3004–7. - PubMed
-
- Park J, Sun D, Genest DR, Trivijitsilp P, Suh I, Crum CP. Coexistence of low and high grade squamous intraepithelial lesions of the cervix: Morphologic progression or multiple papillomaviruses? Gynecol Oncol. 1998;70:386–91. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources